Lookup NU author(s): Tariq AlShehri,
Dr Desa Lilic
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
We demonstrate clinical utility of ruxolitinib, a JAK1/2 inhibitor, in CMC due to STAT1 gain-of-function mutation. We show functional data to explain this effect. This drug is a potentially a transformative therapy for these patients.
Author(s): Higgins E, AlShehri T, McLeer MA, Feighery C, Lilic D, Irvine AD
Publication type: Article
Publication status: Published
Journal: Journal of Allergy and Clinical Immunology
Print publication date: 04/02/2015
Online publication date: 04/02/2015
Acceptance date: 02/02/2015
ISSN (print): 0091-6749
ISSN (electronic): 1097-6825
Altmetrics provided by Altmetric